Manejo da mucosite oral induzida por quimioterapia e radioterapia com laser de baixa potência: resultados iniciais do Hospital A.C. Camargo by Sandoval, Renata Lazari et al.
BMANAGEMENT OF CHEMO- AND
RADIOTHERAPY INDUCED ORAL MUCOSITIS
WITH LOW-ENERGY LASER: INITIAL
RESULTS OF A.C. CAMARGO HOSPITAL
MANEJO DA MUCOSITE ORAL INDUZIDA POR QUIMIOTERAPIA E
RADIOTERAPIA COM LASER DE BAIXA POTÊNCIA: RESULTADOS INICIAIS
DO HOSPITAL A.C. CAMARGO
Renata Lazari SANDOVAL
Resident of the Department of Stomatology at A.C. Camargo Hospital.
Daniel Henrique KOGA
Resident of the Department of Stomatology at A.C. Camargo Hospital.
Lígia Schmitd BULOTO
Resident of the Department of Stomatology at A.C. Camargo Hospital.
Ricardo SUZUKI
Resident of the Department of Stomatology at A.C. Camargo Hospital.
Luciano Lauria DIB
Professor of Stomatology at UNIP.
ackground. Oral mucositis is a common complication of some malignancies treatment, causing therapeutic
modifications due to patient’s debilitation, which often interferes with the prognosis of the disease. Many attempts
have been made to find an optimal treatment or preventive method to minimize the severity of oral mucositis.
Several studies have shown good results with the use of low-energy laser, with the aim of accelerating the process
of wound healing and promoting pain relief. Methods. Patients (n=18) who developed oral mucositis during
chemotherapy and/or radiotherapy were submitted to low-energy laser applications until cessation of symptoms.
Mucositis severity was scored by an oral mucositis scale based on clinical features and by an oral toxicity scale
from the National Cancer Institute based on the ability to swallow; pain severity was scored by subjects on a visual
analogue scale before and after the applications. Results.  Immediate pain relief was achieved in 66.6% of the
patients after the first application. Based on the functional scale, mucositis grade III (not capable to eat solids) was
reduced in 42.85% of the cases. According to the scale based on the clinical features, mucositis grade IV (ulcerative
lesions) was reduced in 75% of the patients that presented this grade of mucositis at the beginning of laser therapy.
Conclusions. Low-energy laser was well-tolerated and showed beneficial effects on the management of oral mucositis,
improving the quality of life during the oncologic treatment.
UNITERMS: Low-energy laser; Soft laser; Oral mucositis.
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INTRODUCTION
Oncologic treatment often involves the use of radiotherapy
and/or chemotherapy. A common acute complication of this
kind of therapy is oral mucositis, which has a great impact in
patient’s quality of life during treatment and sometimes may
lead to treatment interruptions, resulting in severe consequences
in terms of tumor response.
Approximately 60% of patients receiving conventional
radiotherapy for head and neck cancer and more than 90% of
patients submitted to combined therapy (concomitant
chemotherapy and radiotherapy) or altered fractionation are
expected to develop severe oral mucositis9, 11. In addition, up
to 40% of chemotherapy patients develop oral mucositis, mainly
when regimens include 5-FU, methotrexate, cisplatin17. Besides
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all the local discomfort caused by oral mucositis, the ulcerative
lesions bring about a high risk of microbial invasion,
predisposing to local and systemic infections that can be life-
threatening3, 12.
The pathogenesis of oral mucositis is linked to the decreased
cell renewal in the basal layers of the epithelium, due to the
effects of chemotherapy and radiotherapy. According to Sonis18,
oral mucositis progresses through four physiologic phases: 1)
inflammatory or vascular, 2) epithelial, 3) ulcerative and
bacteriological, and 4) healing phase.
Many agents have been tested for prevention and treatment
of mucositis: oral glutamine supplementation10, sucralfate5,
steroids, immunoglobulin, amifostine6, antibiotic lozenges,
chlorhexidine rinses8, vitamin E21, salt and soda mouthwash,
but none of them showed optimal symptom relief and reduction
in the intensity or duration of the lesions.
Nowadays, management of oral mucositis is mostly based
on palliation of the symptoms (topical anesthetics, anti-
inflammatories, systemic analgesic drugs) and prevention of
secondary infections (antimicrobial agents). However,
considering Sonis’ concept18, which describes the physiologic
progression of mucositis, it is mandatory to consider treatments
with mechanisms of action that match with those biological
mechanisms involved in each phase of mucositis. Biron, et al.4
(2000) described very well all the physiologic phases and the
respective treatment options. The most promising procedure
seems to be the use of Low-Energy Laser.
Several trials have demonstrated the use of Low-Energy
Laser (LEL) in the management of oral mucositis. Laser
applications were associated with time of onset delay, peak
severity attenuation and shortened duration of the lesions.
Previous studies have attributed the enhancement of wound
healing and pain relief potential of LEL to microscopic and
molecular findings as increased cell division and modification
of nerve conduction via the release of endorphins and
enkephalins, respectively1, 2, 7, 16.
The aim of the present study is to evaluate the benefits of
low-energy laser therapy in the management of oral mucositis,
as well as the acceptance and compliance of this technique by
the patients treated at our institution.
Patients and Methods
A preliminary prospective study was conducted with all
the patients who developed chemo- and/or radio-induced oral
mucositis from February 2002 to July 2002. The patients were
referred to the Department of Stomatology as soon as symptoms
related to mucositis started.
Patients consisted of 8 females and 10 males, aged 4-82,
who were undergoing chemotherapy and/or radiotherapy for
the treatment of 9 head and neck cancers ( 8 oral squamous
cell carcinomas and 1 nasopharyngeal carcinoma), 5 leukemias,
1 non-Hodgkin lymphoma, 1 Hodgkin’s disease and 3 other
sarcomas. Nine patients were receiving chemotherapy, 3
patients were being submitted to radiotherapy in the head and
neck field, 5 patients were undergoing concomitant
chemotherapy and radiotherapy, and 1 patient had been enrolled
to conditioning chemotherapy for bone marrow transplantation.
Laser applications were performed daily (660nm
wavelength, power 30 mW, 2 Joules/cm2) until cessation of
symptoms. The treatment time for each application point, which
was coincident with the oral lesion, was 1 minute and 6 seconds.
The average energy density delivered for each application point
was 2 Joules/cm2. The total amount of time of each session of
laser therapy depended on the extension and number of lesions.
Mucositis severity was scored by a scale based on clinical
features, and by an Oral Toxicity Scale from the National Cancer
Institute based on the ability to swallow (Table 1); pain severity
was scored by subjects on a visual analogue scale before and
after the applications.
RESULTS
Immediate pain relief after laser application was achieved
in 12 patients (66.6%) during the first application. At the last
application, 16 (88.8%) patients referred immediate pain relief.
On the other hand, during the first application, 6 patients
(33.3%) did not refer any pain relief, which happened with
only 2 patients at the last application (Figure 1).
According to the grading system based on functional
impairments in the beginning of laser therapy, 2 patients
presented mucositis grade I (11.1%), 7 patients showed grade
II (38.8%), 7 patients grade III, and 2 patients grade IV. At the
last application, 4 patients presented grade I (22.2%), 9 patients
grade II (49.9%), 3 patients grade III (16.6%), and 2 patients
grade IV (11.1%). The number of patients receiving nutritional
support did not show any decrease. Mucositis grade III was
reduced in 42.85% of the cases that presented this oral status at
the beginning of the therapy. In addition, the decrease of grade
III (compromised ability to swallow) was associated with an
important increase of grades I and II (Table 2).
Considering the classification of mucositis based on the
clinical aspects, the initial evaluation of the patients showed 3
patients with mucositis grade II (16.6%), 7 grade III (38.8%),
and 8 grade IV (44.4%). At the end of laser therapy, 1 patient
presented grade 0 (5.5%), 4 patients showed grade II (22.2%),
11 had grade III (61.1%) and 2 grade IV (11.1%). Mucositis
grade IV was reduced in 75% of the cases. The decrease in
mucositis grade IV was associated with an increase in mucositis
grade 0, II and III, especially grade II (Table 2).
The number of applications ranged from 1 to 16 applications
and the average number of applications per patient was 5.33.
DISCUSSION
Our study was designed to evaluate the benefits of curative
laser therapy in the management of oral mucositis, regarding
the acceptance and compliance of this technique by the patients,
with emphasis to pain reduction and attenuation of mucositis
severity.
Experimental studies in animals and in vitro studies
conducted during the 1990’s have provided evidence that low-
energy lasers accelerate the process of wound healing. Pourreau-
Schneider, et al14. (1989) reported a twofold increase in the
Number of patients
   Functional grades Clinical grades
Mucositis graduation IS FS IS FS
Grade 0 0 0 0 1
Grade I 2 4 0 0
Grade II 7 9 3 4
Grade III 7 3 7 11
Grade IV 2 2 8 2
IS, initial oral status; FS, final oral status.
TABLE 2- Oral status before and after laser therapy, according to clinical and functional aspects
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  Grade
Type of score   0 I II    III     IV
Clinical
parameters no change whitish aspect erythema white coating ulcers
Functional
impairments no symptoms soreness mild pain/can can´t eat solids/ require nutritional
solids liquids eat  support
TABLE 1- Oral mucositis grading scores
number of gingival fibroblasts that had received laser irradiation
compared to that of untreated controls. In addition, by means
of transmission electron microscopy they observed that the laser
induced modifications in the ultrastructure of the treated cells,
causing mitochondrial hyperplasia and deposition of an
abundant fibrillar matrix. Even though the precise mechanisms
involved have not yet been elucidated, some possible partial
explanations have been reported. A number of cellular
components manifest photoactivation by bioelectrical reactions.
The energy absorbed at the mitochondrial level could be
available for photochemical reactions. The absorption of
photons by cytochromes, present in large numbers in
mitochondrial crests, could lead to an enhancement of protein
synthesis15.
The recent literature reveals that the prophylactic laser
therapy seems to be more effective than the curative approach,
but there are also good results showing pain relief achieved by
curative laser applications. In 1992, Pourreau-Schneider, et al.16
published a preliminary report showing the benefits of LEL
therapy in cancer patients receiving high-dose fluorouracil.
Several malignancies were included in the study, including head
and neck cancer, breast, colon and others. The patients were
divided in three groups: a control group (without laser therapy),
a preventive group (laser therapy prior to and during
chemotherapy) and a curative group. The incidence and severity
of oral mucositis were calculated according to the total cycles
of chemotherapy. In the control group, mucositis occurred in
43% of 51 chemotherapy cycles. In the curative group, the
time to repair grade IV lesions (ulcerations, no oral uptake)
was reduced from a mean of 19.3 days in the control patients
to 8.1 days. In the preventive group, only low-grade mucositis
occurred.
The data obtained in our study showed an improvement of
the oral status at the end of laser therapy, considering both
aspects: functional and clinical. Functional mucositis grade III
(cannot eat solids/liquids) was reduced in 42.85% of the cases
that presented this grade at the beginning of therapy. In addition,
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clinical mucositis grade IV (ulcers) was reduced in 75% of the
cases. Although it was possible to observe a reduction in
mucositis severity, it did not allow an evaluation of the exact
duration of the lesions, since the patients were referred to our
department only when they became symptomatic and laser
applications were suspended as soon as pain cessation was
achieved, even though there was still clinical evidence of
mucositis. The number of applications needed for the
achievement of symptoms cessation ranged from 1 to 16
applications and the average number of applications per patient
was 5.33.
Radio- and chemo-induced oral mucositis have different
peaks of severity and improvement. Radio-induced oral
mucositis may appear after 3-4 weeks of treatment, and their
evolution is progressive if radiation therapy is not ceased. On
the other hand, oral mucositis related to chemotherapy tends to
increase 1-2 weeks after the start of treatment, followed by
improvement.13 In our sample, 9 patients were submitted to
chemotherapy and 8 patients were submitted to radiotherapy
alone or in combination with chemotherapy.
Bensadoun, et al.2 (1999) performed a randomized phase
III trial in which laser therapy was administered in a preventive
and curative form following the 7-week treatment of patients
with head and neck cancer receiving radiotherapy alone. The
group of patients that did not receive laser therapy (L-) showed
mucositis grade 3 (confluent ulcers, liquid diet only; according
to WHO staging) during 35.2% of the weeks, and this number
fell to 7.6% in the group that received the laser (L+). In addition,
the frequency of severe pain was 23.8% in the L- group and
1.9% in the L+ group. In the present study, despite the elevated
number of patients that presented grade 3 mucositis (white
coating) at the end of laser therapy, this finding is probably
related to the healing process of the lesions, since there were
no associated symptoms. This fact reveals an old problem
related to effective scoring of mucositis. Sonis, et al.19 (1999)
demonstrated a strong correlation between objective patterns
(clinical appearance of oral mucositis) and symptoms during a
validation study of an oral mucositis scoring system, however,
it could not be shown in ours. Other validation studies with
enough tools and relevant endpoints are needed.
Patients undergoing bone marrow transplantation (BMT)
are also widely approached by low-energy laser trials. Cowen,
et al.7 (1997) showed a 33% reduction of severe mucositis in
patients submitted to laser therapy during conditioning regimen
for BMT. The assessment of oral pain was based on the need
of morphine administration, which was significantly reduced
by laser applications (p=0.05). This finding is in agreement
with the study conducted by Bensadoun2. In our study, the pain
severity was scored in a subjective way by the patients. It was
assessed before and after laser applications. Immediate pain
relief after laser application was referred by 66.6% of the
patients during the first application, and at the last application,
it happened with 88.8% of the patients. In a double-blind study
of pain relief due to LEL, a large increase in the urinary excretion
of 5-hydroxyindoleacetic acid was found in patients who
received LEL treatment, what suggested that LEL treatment
may affect the serotonin metabolism.22 Another possible
mechanism related to the analgesic effect of LEL was described
by Snyder-Mackler and Bork in 1988. 20 They documented a
physical finding concerning an interference in the sensory nerve
transmission caused by laser irradiation. However, in our study,
persistent oral pain was demonstrated in 12.2% of the patients,
and this could be a consequence of the association of other
pathologies, such as herpes infection.
Aspects related to the duration of mucositis and peak
severity attenuation were not statistically calculated and
discussed in our study because of the diversity of pathologies
and respective treatments present in our sample. The age range,
distribution of patients by diagnosis and therapeutic regimens
(chemotherapy, radiotherapy, concomitant chemotherapy and
radiotherapy, conditioning for blood marrow transplantation)
were variables that were extremely difficult to control in such a
small sample. In addition, several factors could influence the
development, severity and duration of oral mucositis, including
the underlying disease, treatment schedule, doses, combination
and duration of exposure to drugs and/or ionizing radiation,
systemic clearance of drugs, local and microbial irritation,
among others.
Finally, there are many uncontrolled reports of potential
benefits of low-energy lasers, but only a few controlled studies
have been published. Despite the small and heterogeneous
characteristic of our sample, it is evident that LEL is a non-
invasive technique that seems to promote pain relief and reduce
the severity of oral mucositis; for this reason, patients present a
high acceptance and compliance to this therapy, even the
youngest ones. After the present study, the use of LEL in the
management of oral mucositis became a routine at our
institution. Further randomized controlled trials with
homogeneous samples and different laser application schedules
should be conducted with the aim to develop effective protocols
to treat and prevent such debilitating complication as oral
mucositis.
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RESUMO
Mucosite é a complicação oral mais comum do
tratamento de algumas doenças malignas, podendo causar
a necessidade de modificações terapêuticas, o que pode
interferir com o prognóstico da doença. Muitas tentativas
têm sido feitas com o intuito de desenvolver um tratamento
ou método preventivo para minimizar a severidade da
mucosite oral. Vários estudos têm mostrado bons resultados
com o uso do laser de baixa potência, devido à aceleração
do processo de cicatrização das lesões e da promoção do
alívio da dor. Métodos: Os pacientes que desenvolveram
mucosite oral durante tratamento quimioterápico e/ou
radioterápico (n=18), foram submetidos a aplicações de laser
de baixa potência até que fosse atingida a cessação dos
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sintomas. A severidade da mucosite foi avaliada através de
uma escala baseada em características clínicas e de uma
escala para avaliação de toxicidade oral desenvolvida pelo
Instituto Nacional do Cancer, baseada na habilidade de
deglutição; a dor foi avaliada através de uma escala visual,
antes e depois de cada aplicação. Resultados: Alívio
imediato da dor após a primeira aplicação foi referido por
66.6% dos pacientes. Com base na escala funcional,
mucosite grau III (incapacidade de ingerir alimentos sólidos)
foi reduzida em 42.85% dos casos. De acordo com a escala
baseada em aspectos clínicos, mucosite grau IV (presença
de úlceras) foi reduzida em 75% dos pacientes que
apresentavam essa condição no início da terapia com laser.
Conclusões: O laser de baixa potência foi bem tolerado pelos
pacientes, e mostrou efeitos benéficos durante o manejo da
mucosite oral, melhorando a qualidade de vida dos pacientes
durante o tratamento oncológico.
UNITERMOS: Laser de baixa potência; Mucosite oral.
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